Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
12 November 2018 - 11:00PM
Mersana Chief Scientific Officer, Timothy
B. Lowinger, Ph.D. to chair 2018 Conference
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody drug conjugates (ADCs) based on its
Dolaflexin® and other proprietary platforms, today announced that
members of the senior management and scientific teams will present
at the upcoming World ADC 2018 conference in San Diego, CA,
November 12-14, 2018.
“As an emerging leader in ADCs, Mersana is honored to play such
a prominent role at this year’s ADC World Conference.,” said
Timothy B. Lowinger, Ph.D., Chief Scientific Officer, Mersana
Therapeutics, and Chairman, World ADC 2018. “The information
presented and shared at this important conference by my Mersana
colleagues and other industry leaders helps reinforce the rapid
pace of innovation in the ADC field and the important role ADCs
play in addressing significant unmet medical needs.”
Mersana will participate in the following World ADC
presentations:
Title: Analytical Characterization of Dolaflexin ADCs Date/Time:
Monday, November 12, 2018, 11:45 – 12:15 p.m.Presenter: David Lee,
Ph.D., Senior Director, Analytical Chemistry, Mersana Therapeutics
Title: Utilizing Panels of Patient-derived Xenografts to Aid
the Development of ADCs Date/Time: Tuesday, November 13, 2018, 1:30
– 2:00 p.m.Presenter: Scott D. Collins, Manager, Pharmacology,
Mersana Therapeutics Title: Formulation Development Challenges for
a Novel Dolaflexin ADC platformDate/Time: Tuesday, November
13, 2018, 1:30 – 2:00 p.m.Presenter: Sandra O’Connor, Executive
Director, Sterile Drug Products, Mersana TherapeuticsTitle: High
DAR ADCs with a Controlled Bystander Effect: From Concept to
Clinical ExperienceDate/Time: Wednesday, November 14, 2018, 9:00 –
9:30 a.m.Presenter: Timothy B. Lowinger, Ph.D., Chief Scientific
Officer, Mersana Therapeutics
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical
company using its differentiated and proprietary ADC platforms to
develop highly targeted drugs with increased tolerability and
expanded opportunities to deliver meaningful clinical benefit to
patients. Mersana’s product candidate XMT-1522 is in Phase 1
clinical trials in patients with advanced tumors expressing HER2,
including breast cancer, non-small-cell-lung-cancer (NSCLC) and
gastric cancer patients. The Company’s second product candidate,
XMT-1536, is in Phase 1 clinical trials in patients with tumors
expressing NaPi2b, including ovarian cancer, NSCLC and other
cancers. In addition, multiple partners are using Mersana’s
platform to advance their ADC pipelines.
Media Contact Paul Kidwell
paulkidwell@mersana.com 617-680-1088
Investor Contact Stern Investor Relations, Inc.
Christina Tartaglia christina@sternir.com 212-362-1200
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2024 to May 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From May 2023 to May 2024